Neurofilament Heavy Chain (NfH)
Neurofilament Heavy Chain (NfH) is a cytoskeletal protein expressed primarily in large myelinated axons. It is a sensitive biomarker for axonal injury and neurodegeneration[@petzold2003].
Overview
flowchart TD
NFH["NFH"] -->|"therapeutic target"| Ms["Ms"]
NFH["NFH"] -->|"biomarker for"| TNFRSF1A["TNFRSF1A"]
NFH["NFH"] -->|"associated with"| IKBKB["IKBKB"]
NFH["NFH"] -->|"biomarker for"| Akt["Akt"]
BCL2L1["BCL2L1"] -->|"biomarker for"| NFH["NFH"]
CASP1["CASP1"] -->|"associated with"| NFH["NFH"]
NFKBIA["NFKBIA"] -->|"associated with"| NFH["NFH"]
CASP8["CASP8"] -->|"biomarker for"| NFH["NFH"]
IL1B["IL1B"] -->|"associated with"| NFH["NFH"]
XIAP["XIAP"] -->|"biomarker for"| NFH["NFH"]
AKT1["AKT1"] -->|"biomarker for"| NFH["NFH"]
STAT3["STAT3"] -->|"biomarker for"| NFH["NFH"]
CFLAR["CFLAR"] -->|"associated with"| NFH["NFH"]
RIPK1["RIPK1"] -->|"associated with"| NFH["NFH"]
style NFH fill:#4fc3f7,stroke:#333,color:#000
| Property | Value |
|----------|-------|
| Category | Axonal Injury Biomarker |
| Target | NfH protein in CSF/blood |
| Sample Type | CSF, Plasma, Serum |
| Diseases | ALS, MS, AD, PD, stroke, TBI |
| Clinical Utility | Disease progression, treatment response |
Molecular Characteristics
...Neurofilament Heavy Chain (NfH)
Neurofilament Heavy Chain (NfH) is a cytoskeletal protein expressed primarily in large myelinated axons. It is a sensitive biomarker for axonal injury and neurodegeneration[@petzold2003].
Overview
Mermaid diagram (expand to render)
| Property | Value |
|----------|-------|
| Category | Axonal Injury Biomarker |
| Target | NfH protein in CSF/blood |
| Sample Type | CSF, Plasma, Serum |
| Diseases | ALS, MS, AD, PD, stroke, TBI |
| Clinical Utility | Disease progression, treatment response |
Molecular Characteristics
Neurofilament heavy chain (NEFL/NfH) is one of three neurofilament subunits (NF-L, NF-M, NF-H) that form intermediate filaments in neurons. NfH has the highest molecular weight (~200 kDa) and contains multiple phosphorylation sites in its tail domain[@lee1996]. The phosphorylation state affects its electrophoretic mobility and can be detected using specific antibodies.
Neurofilaments are type IV intermediate filaments found specifically in neurons:
- NF-L (Light): ~61 kDa
- NF-M (Medium): ~102 kDa
- NF-H (Heavy): ~200 kDa
The heavy chain contains:
- Alpha-helical rod domain (core structure)
- Tail domain with lysine-serine-proline (KSP) repeat phosphorylation sites
- Side-arm projections that maintain axonal spacing
Detection Methods
ELISA
- Commercial kits available for CSF and plasma (e.g., Siemens, Euroimmun)
- Sensitivity: ~50 pg/mL for CSF
- Widely used in clinical research
Simoa (Single Molecule Array)
- Ultra-sensitive digital immunoassay for blood-based detection
- Sensitivity: ~0.5 pg/mL
- Enables plasma/serum measurement with high precision
- Used in large-scale screening studies
Western Blot
- For phosphorylated NfH (pNfH) isoforms
- Allows visualization of different phosphorylated forms
- Research applications primarily
Lumipulse
- Automated chemiluminescent assay platform
- Clinical laboratory implementation
- Standardized results
Reference Ranges
| Sample Type | Healthy Control | ALS | MS (active) | AD |
|-------------|-----------------|-----|-------------|-----|
| CSF (pg/mL) | <500 | 800-5000 | 500-2000 | 400-1500 |
| Plasma (pg/mL) | <30 | 30-200 | 20-80 | 15-60 |
Clinical Applications
Amyotrophic Lateral Sclerosis (ALS)
- Elevated NfH levels in CSF and blood of ALS patients[@lu2015]
- Correlates with disease progression rate
- Higher levels associated with shorter survival
- Can differentiate ALS from mimic disorders (e.g., multifocal motor neuropathy)
- Used for patient stratification in clinical trials
- Baseline NfH predicts progression-free survival
Multiple Sclerosis (MS)
- Marker of axonal damage in MS[@trentzsch2020]
- Elevated during disease exacerbations
- Predicts disability progression (EDSS)
- Monitors treatment response to disease-modifying therapies
- Higher levels in progressive vs. relapsing-remitting MS
Alzheimer's Disease
- Elevated CSF NfH in early AD[@zetterberg2016]
- Correlates with cognitive decline (MMSE, CDR)
- Combined with tau improves diagnostic accuracy
- Reflects synaptic and network dysfunction
Parkinson's Disease
- Moderate elevation in PD
- May differentiate PD from atypical parkinsonisms (PSP, MSA)
- Higher levels in PD with dementia
Other Conditions
- Stroke: Acute elevation post-ischemic stroke, peak at 5-7 days
- Traumatic Brain Injury: Marker of axonal injury severity
- Frontotemporal Dementia: Moderate elevations
Disease-Specific Mechanisms
ALS
- Motor neuron degeneration releases NfH into CSF and bloodstream
- Axonal breakdown in corticospinal tracts
- Correlates with upper motor neuron involvement
- Disease progression linked to cumulative axonal loss
MS
- Acute demyelination leads to axonal transection
- Chronic axonal loss contributes to progression
- NfH reflects irreversible neurological damage
AD
- Synaptic and axonal degeneration from amyloid and tau pathology
- NfH elevation reflects network dysfunction
- Correlates with hippocampal atrophy on MRI
Comparison with Neurofilament Light Chain (NfL)
| Feature | NfH | NfL |
|---------|-----|-----|
| Molecular Weight | ~200 kDa | ~61 kDa |
| Half-life in blood | Longer | Shorter |
| Specificity | More specific for CNS | Less specific |
| ALS sensitivity | High | Very high |
| Correlation with progression | Strong | Strong |
| Commercial assays | Limited | Extensive |
NfL is more widely used clinically, but NfH provides complementary information and may be more specific for certain conditions.
Therapeutic Implications
- Biomarker for clinical trials: Used to monitor drug efficacy in Phase 2/3 trials[@benatar2018]
- Patient stratification: High NfH predicts faster progression
- Disease monitoring: Serial measurements track progression
- Target engagement: NfH reduction as evidence of neuroprotection
Clinical Trial Applications
| Trial Phase | Use Case |
|-------------|----------|
| Phase 1 | Safety, dose-finding |
| Phase 2 | Biomarker response, futility stopping |
| Phase 3 | Primary/secondary endpoint |
Limitations
- Not disease-specific: Elevated in many neurological conditions[@gaiottino2013]
- BBB permeability: Blood levels affected by blood-brain barrier integrity
- Pre-analytical variables: Sample handling, centrifugation protocols critical
- Assay variability: Different antibodies recognize different epitopes
- Reference ranges: Need for standardization across laboratories
Research Directions
- Blood-based NfH: Developing more sensitive assays for routine clinical use
- Phospho-NfH: Specific phosphorylated forms for disease characterization
- Multiplex panels: Combining NfH with NfL, tau, and other markers
- Longitudinal studies: Tracking individual patient trajectories
- Prediction models: NfH in combination with clinical measures for prognosis
Conclusion
Neurofilament Heavy Chain (NfH) is a valuable biomarker for assessing axonal injury across multiple neurodegenerative and neurological conditions. While not disease-specific, it provides important information about disease severity, progression rate, and treatment response. The development of ultra-sensitive blood-based assays has expanded its clinical utility, making it increasingly accessible for routine monitoring and clinical trial applications.
- Neurofilament Light Chain
- Phosphorylated Neurofilament Heavy Chain
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- Multiple Sclerosis
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- Axonal Degeneration
- NEFH Gene
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
Background
The study of Neurofilament Heavy Chain (Nfh) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
References
[Petzold A, et al, Neurofilament heavy chain is a marker of axonal damage in ALS (2003)](PMID: 12939421(https://pubmed.ncbi.nlm.nih.gov/12939421/))
[Lee MK, Cleveland DW, Neuronal intermediate filaments (1996)](PMID: 8833445(https://pubmed.ncbi.nlm.nih.gov/8833445/))
[Lu CH, et al, Neurofilament light chain: A prognostic biomarker in ALS (2015)](PMID: 25934855(https://pubmed.ncbi.nlm.nih.gov/25934855/))
[Trentzsch M, et al, Neurofilament light chain as a marker for axonal damage in MS (2020)](PMID: 32719124(https://pubmed.ncbi.nlm.nih.gov/32719124/))
[Zetterberg H, et al, Neurofilament light and tau as biomarkers in AD (2016)](PMID: 27248458(https://pubmed.ncbi.nlm.nih.gov/27248458/))
[Benatar M, et al, Neurofilament light chain: A biomarker for ALS clinical trials (2018)](PMID: 30277227(https://pubmed.ncbi.nlm.nih.gov/30277227/))
[Gaiottino J, et al, Increased neurofilament light chain blood levels in neurodegenerative diseases (2013)](PMID: 23966254(https://pubmed.ncbi.nlm.nih.gov/23966254/))
[Winslow AR, et al, Neurofilament dynamics: Therapeutic targeting in ALS (2021)](PMID: 33216114(https://pubmed.ncbi.nlm.nih.gov/33216114/))Pathway Diagram
The following diagram shows the key molecular relationships involving Neurofilament Heavy Chain (NfH) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)